The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes

5-Azacytidine (5AC), a hypomethylating agent, is clinically used for the treatment of patients with myelodysplastic syndromes (MDS). Cytidine deaminase (CDA) is a key enzyme in the detoxification of 5AC. We investigated whether the CDA expression could predict response to 5AC in MDS. Among leukemia-...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncotarget
मुख्य लेखकों: Murakami, Yuichi, Kimura, Yoshizo, Kawahara, Akihiko, Mitsuyasu, Shohei, Miyake, Hidetoshi, Tohyama, Kaoru, Endo, Yoshio, Yoshida, Nao, Imamura, Yutaka, Watari, Kosuke, Ono, Mayumi, Okamura, Takashi, Kuwano, Michihiko
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Impact Journals LLC 2019
विषय:
Research Paper
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6481348/
https://ncbi.nlm.nih.gov/pubmed/31040918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26784
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन